DOE Isotope Program, Bayer Finalize Major Contract for Supply of Ac-227

NIDC thumbnail
The US Department of Energy Isotope Program has agreed to terms with Bayer on a 10-year supply contract for actinium-227 (Ac-227) to support the company’s anticipated market growth of Xofigo®, a drug proven to prolong survival and improve the quality of life for patients with prostate cancer that has metastasized to the skeleton. The Ac-227 is produced at and shipped from Oak Ridge National Laboratory (ORNL). Upon arrival in Norway, Bayer will periodically extract radium-223, the active ingredient in Xofigo®, from the decaying Ac-227 and ship it to treatment facilities in 52 countries where it is now approved.
See the full press release from ORNL.